Belgische aandelen « Terug naar discussie overzicht

Eckert-Ziegler

77 Posts, Pagina: « 1 2 3 4 | Laatste
ws belgie
0
vandaag heb ik er nog 15K bijgekocht. nu een totale positie van 30k met een gemiddelde van 2.01€. laat ons hopen dat het nu nog eens zal lopen zoals vorig jaar rond de jaar wisseling
[verwijderd]
1
[verwijderd]
0
Gaat in 2013 een mooi aandeel zijn, net voor de jaar afsluit "goed nieuws" gebracht heb ze aangekocht aan 1,88 en heb nu reeds mooie winst (12,24 %)

(BTW, heel de portefeuille staat "FEL" groen (behalve CMB, maar dat trekt zich in 2013 wel recht)

:-)
Nel
0
aandeel moet eerst tot rust komen,na de doorbraak ,zal daarna richting de 2,50 gaan,aan de cijfers zal het niet liggen hahaha

en tevens wachtende op een eventuweel bod

succes
ws belgie
0
quote:

NEL schreef op 3 januari 2013 15:48:

aandeel moet eerst tot rust komen,na de doorbraak ,zal daarna richting de 2,50 gaan,aan de cijfers zal het niet liggen hahaha

en tevens wachtende op een eventuweel bod

succes
zit je er intussen al in?
Nel
0
Seneffe, Belgium, November 4, 2013, Eckert & Ziegler BEBIG announces to have received an order for the delivery of their state-of-the art MultiSource® afterloaders for HDR brachytherapy representing one of the largest single orders ever received by the company. The decision in favour of MultiSource® was driven by the systems unique miniaturized cobalt-60 source as well as exclusive safety features enabling for a high level of accuracy. "Due to its technical characteristics and the long half-life of the isotope used, our afterloader is ideal for the region. The radiation source only needs to be replaced every five years," said Abel Luzuriaga, Managing Director of Eckert & Ziegler BEBIG. A part of the ordered devices will already be delivered within the next month while the remaining afterloaders are expected in Bangladesh in the first quarter of 2014. The deal has a total value of around 3.1 million € and is a positive result of our increased sales activities in that region. "We are pleased to see that emerging countries in Asia, Africa and South America are increasingly gaining access to the latest medical infrastructure that has long been available in other parts of the world. Our range of MultiSource® devices with their distinguished characteristics is exactly what decision-makers are looking for," Abel Luzuriaga added. The tender was advertised in the context of the "Health, Population & Nutrition Sector Development Program (HPNSDP)". Amongst others, the five year program aims to enhance the cancer treatment in The People's Republic of Bangladesh that is facing rising incidences of the disease. It is the third sector-wide program of its kind in the country. Supported by the European Union, the World Bank, UNICEF, the World Health Organization (WHO) and 17 more development partners, the program will end in June 2016. - See more at: www.beursig.nl/forum/viewtopic.php?f=...
Nel
0
Eckert & Ziegler BEBIG announces the manufacturing and distribution of its globally respected Low Dose Rate Brachytherapy Products in the U.S. Seneffe - Belgium, December 9, 2013. Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB) is pleased to announce that it is resuming production and distribution in its recently acquired manufacturing facility in Oxford, Connecticut (USA). Following delivery of individual products in the past few weeks, the full LDR brachytherapy portfolio, which includes the innovative core products AnchorSeed® and VariStrand(TM), is now once again available to American customers."Taking up production again at our new manufacturing facility in Connecticut marks a milestone in our company's history. We are pleased to announce that the remediation work has been completed successfully so we can once again supply our valued brachytherapy products 'Made in the USA' to the American market in the usual way," explained Dr. Edgar Löffler, Managing Director of Eckert & Ziegler BEBIG.Eckert & Ziegler BEBIG took over the business unit in Oxford from Biocompatibles with effect November 1, 2013. Biocompatibles had voluntarily suspended manufacture and delivery of its products in May 2013 after a warning letter from the FDA claiming shortcomings in its documentation of the manufacturing process.About Eckert & Ziegler BEBIG Contributing to saving lives!Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with subsidiaries throughout Europe, in the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.

Eckert & Ziegler Bebig neemt een pionier in brachytherapie over, het Amerikaanse bedrijf Mick Radio Nuclear Instruments (MRNI). Een overnameprijs is niet bekendgemaakt. MRNI tekende in het boekjaar 2012/2013 voor een omzet van omgerekend 4 miljoen euro. MRNI is een van de leidinggevende bedrijven in de ontwikkeling van applicatoren voor brachytherapie. Daarbij worden kankertumoren bestraald door middel van radioactieve implantaten. MRNI werd in 1972 opgericht en is gevestigd in Mount Vernon, New York. Met de overname van MRNI zet Eckert & Ziegler Bebig zijn expansie in de Verenigde Staten verder. Eerder kondigde de groep al aan de brachytherapie-activiteiten van Biocompatibles over te nemen. - See more at: beursig.nl/forum/viewtopic.php?f=4&am...
Nel
0
men gaf aan dat men een sterk 4Q verwachte dus met de overnamens die zijn gedaan en vooruitzichten wil ik wel eens zien hoelang het moederbedrijf die laatste aandelen op de markt laat.

Nel
0
Overall market development of our core business continues to be positive, and Eckert & Ziegler BEBIG’s order bookings grew by 10% compared to last year.

sale ging om deze reden omlaag

Overall, revenues were lower than in 2012, as our ongoing core business was unable to recover from the impact of last year’s ZAO MSM-Medimpex agreement and from the changes of eliminating a part of our unprofitable merchandise business in France.

ev er aandeel weer gestegen naar 2,64
gaat een mooi jaar worden deals die komen gaan.
www.bebig.eu/fileadmin/ibt-bebig.eu/f...
77 Posts, Pagina: « 1 2 3 4 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
718,34  -5,34  -0,74%  07 dec
 Germany40^ 14.285,80 +0,17%
 BEL 20 3.706,62 -0,66%
 Europe50^ 3.928,43 +0,19%
 US30^ 33.587,84 0,00%
 Nasd100^ 11.484,15 0,00%
 US500^ 3.931,62 0,00%
 Japan225^ 27.570,12 0,00%
 Gold spot 1.786,12 +0,02%
 EUR/USD 1,0511 +0,43%
 WTI 72,38 -2,65%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

VIVORYON THER... +2,96%
MAJOREL GROUP... +2,56%
Corbion +1,99%
Alfen N.V. +1,72%
JDE PEET'S +1,65%

Dalers

OCI -8,23%
EBUSCO HOLDING -3,41%
SBM Offshore -3,35%
Basic-Fit -3,01%
ASMI -2,99%